Within gastric and gastroesophageal junction (GEJ) adenocarcinoma, strategies such as angiogenesis inhibition, cytotoxic therapy, and most recently, immunotherapy, are all beginning to have more refined roles in the treatment paradigm, explained J. Stuart Salmon, MD
Immunotherapy Shakes Up Gastric/GEJ Cancer Space, Alongside Angiogenic, Cytotoxic Agents